Warner Chilcott clinical trials

Acquired by AbbVie, May 8, 2020 · source ↗

The registry lists 58 studies whose lead sponsor is Warner Chilcott. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jun 9, 2022.

Studies

Recruiting first, then most recently updated. Showing 50 of 58. List all 58 → · All AbbVie studies →

• A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor OveractivityTerminatedNCT00712322Phase 2

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Safety & Efficacy WC3011 (Estradiol Vaginal Cream) in the Treatment of Vulvovaginal Atrophy in Postmenopausal WomenCompletedNCT01400776Phase 3

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Multicenter Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal WomenCompletedNCT01816139Phase 3

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal Women With DyspareuniaCompletedNCT01845649Phase 3

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Evaluate Long-Term Safety and Efficacy WC3011 (Estradiol Vaginal Cream)CompletedNCT01455597Phase 3

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• A Safety and Efficacy Study of Estradiol Vaginal Capsule in Postmenopausal Women With Vulvovaginal AtrophyCompletedNCT02670785Phase 2

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal WomenCompletedNCT00918749Phase 2

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic HyperplasiaCompletedNCT01939184Phase 2

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Safety and Efficacy of Two Different Doses of Asacol in the Treatment of Moderately Active Ulcerative ColitisCompletedNCT00073021Phase 3

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Treatment of Erectile Dysfunction IICompletedNCT01037218Phase 3

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Treatment of Erectile Dysfunction - Long Term Safety and EfficacyCompletedNCT01065012Phase 3

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Efficacy & Safety of Single Dose Alprostadil Cream (2 Concentrations Enhancer) to Vehicle in Men w/Erectile DysfunctionTerminatedNCT01810575Phase 2

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Analysis of Iliac Crest Biopsies From Patients Receiving RisedronateCompletedNCT00837746

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Study of Bone Histomorphometry, Microarchitecture, and Matrix Structure in Patients Receiving Alendronate or RisedronateCompletedNCT00778154

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Fecal Biomarker Study for Patients With Ulcerative ColitisCompletedNCT00780507

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• A Study of Monthly Risedronate for OsteoporosisCompletedNCT00247273Phase 3

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Treatment of Moderate to Severe Facial Acne VulgarisCompletedNCT00612573Phase 2

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• A Study of a 35 mg Delayed Release Formulation of Risedronate for OsteoporosisCompletedNCT00541658Phase 3

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Bone Microarchitecture in Osteopenic Postmenopausal WomenTerminatedNCT00577395Phase 4

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Asacol Acute Diverticulitis(DIVA)StudyCompletedNCT00554099Phase 2

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Study of Safety and Efficacy of an Oral ContraceptiveCompletedNCT00932321Phase 3

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Hormone Replacement Therapy for Use in Postmenopausal Women for Relief of Hot Flushes and Urogenital Symptoms.CompletedNCT01070979Phase 3

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• A Comparison of Once a Day Dose Compared to 2 Doses/DayCompletedNCT00505778Phase 3

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Study of Safety and Efficacy of an Oral ContraceptiveCompletedNCT00391807Phase 3

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in ChildrenCompletedNCT00106028Phase 3

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Study of Safety and Efficacy of an Oral ContraceptiveCompletedNCT00477633Phase 3

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Study to Assess the Efficacy/Safety of Transdermal Testosterone Patches in Naturally Menopausal Women With Low LibidoCompletedNCT00349791Phase 3

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Testosterone Therapy in Naturally Menopausal Women With Low Sexual Desire Receiving Transdermal EstrogenCompletedNCT00384046Phase 3

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low LibidoCompletedNCT00331214Phase 3

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Study of Transdermal Testosterone Patches in Naturally Menopausal Women With Low LibidoCompletedNCT00338312Phase 3

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Study of Transdermal Testosterone Patches in Menopausal Women With Low LibidoCompletedNCT00131495Phase 3

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low LibidoCompletedNCT00331123Phase 3

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• A Study of Asacol Absorption, Metabolism and Excretion in Children and Adolescents With Ulcerative Colitis.TerminatedNCT00254618Phase 1

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral DoseCompletedNCT00577850Phase 1

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Pharmacokinetics of Asacol 2.4 g/Day and Lialda 2.4 g/Day in Healthy VolunteersCompletedNCT00751699Phase 1

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Safety, Pharmacokinetics, and Efficacy of 100, 150, and 200 mg Risedronate Administered to Women With Low BMDCompletedNCT00577837Phase 2

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• A Double Blind Study for the Treatment of Acute Ulcerative ColitisCompletedNCT00350415Phase 3

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Bioequivalence of Testosterone Reduced-size Patch Relative to the Testosterone Reference PatchCompletedNCT00791856Phase 1

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Assess Bioequivalence of One 150 mg Risedronate Tablet Versus Two 75 mg Risedronate Tablets in Healthy SubjectsCompletedNCT00699777Phase 1

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative ColitisTerminatedNCT01004185Phase 3

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Treatment of Acne Vulgaris With Doryx Tablets Compared to Doxycyline HyclateCompletedNCT00635609Phase 4

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents With Active Ulcerative ColitisCompletedNCT00713310Phase 3

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Treatment of Chlamydia Infection Comparing WC2031 Tablets With VibramycinCompletedNCT01113931Phase 3

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Assess the Safety, Efficacy, and Pharmacokinetics of Immediate and Delayed Release Weekly RisedronateCompletedNCT00577720Phase 2

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Assessing the Safety/Efficacy of Transdermal Testosterone in Female Patients With Symptomatic Heart FailureTerminatedNCT00957034Phase 2

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Study of the Effect of Once a Week Risedronate on the Microstructure of Tibia and Radius Using a New Scanning MethodCompletedNCT00386360Phase 3

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Treatment of Erectile Dysfunction ICompletedNCT01037244Phase 3

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal WomenCompletedNCT00467259Phase 3

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Effect of Udenafil on SpermatogenesisCompletedNCT01230541Phase 1

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie

• Effect of Stopping Risedronate After Long Term Treatment on Bone TurnoverCompletedNCT01249261Phase 3

  Sponsor listed in the registry: Warner Chilcott · First submitted before Warner Chilcott became part of AbbVie